The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We ...

If authorised, Vimkunya would be the first vaccine in the EU to protect adolescents aged 12 to 17 against Chikungunya.

About Bavarian NordicBavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing ...

The details for each transaction made under the share repurchase program are published on bavarian-nordic.com. Following these transactions, Bavarian Nordic holds a total of 1,044,510 treasury ...

First chikungunya vaccine recommended by the CHMP for persons as young as 12 years old.The virus-like particle (VLP) single-dose chikungunya vaccine is expected to launch in key European markets in ...

Financial guidance for 2025 in line with the Company's 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial ...